Day 4 clinical response of ceftaroline fosamil versus ceftriaxone for community-acquired bacterial pneumonia

Infectious Diseases in Clinical Practice

Volumn 20, Issue 4, 2012, Pages 254-260

  Eckburg, Paul B ^a   Friedland, H David ^a   Llorens, Lily ^a   Smith, Alexander ^a   Witherell, Gary W ^a   Laudano, Joseph B ^b   Thye, Dirk ^a  

^a Cerexa Inc   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

ceftaroline fosamil; clinical response; community acquired bacterial pneumonia (CABP); early end points of symptoms and signs of stability

Indexed keywords

CEFTAROLINE FOSAMIL; CEFTRIAXONE;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84863816231     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0b013e318255d65f     Document Type: Article

References (28)

1. Xu JQ, Kochanek KD, Murphy SL, et al. Deaths: Final Data for 2007. National Vital Statistics Reports. Vol 58, No. 19 Hyattsville, MD: National Center for Health Statistics; 2010. Available at: http://www.cdc.gov/nchs/data/ nvsr/nvsr58/nvsr58-19.pdf. Accessed September 11, 2011.
2. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122:130-141.
3. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39:1642-1650.
4. Drehobl MA, De Salvo MC, Lewis DE, et al. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest. 2005;128:2230-2237.
5. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia [published correction appears in Clin Infect Dis 2011;52:967]. Clin Infect Dis. 2010;51(12):1395-1405.
6. Gotfried MH, Dattani D, Riffer E, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther. 2002;24:736-751.
7. Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008;61:329-338.
8. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry community-acquired bacterial pneumonia: developing drugs for treatment. 2009. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM123686.pdf. Accessed September 11, 2011.
9. US FDA Briefing Document. Anti-infective drugs advisory committee meeting. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia and complicated skin and skin structure infections. 2010. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/ drugs/anti-infectivedrugsadvisorycommittee/ucm224656.pdf. Accessed September 11, 2011.
10. Evans GM, Gaisford WF. Treatment of pneumonia with 2-(p- aminobenzenesulphonamido) pyridine. Lancet. 1938;232:14-19.
11. Finland M, Spring WC Jr, Lowell FC. Specific treatment of the pneumococcic pneumonias; an analysis of the results of serum therapy and chemotherapy at the Boston City Hospital from July 1938 through June 1939. Ann Intern Med. 1940;13:1567-1593.
12. Finland M, Lowell FC, Spring WC Jr. Clinical and laboratory studies on the use of serum and sulfapyridine in the treatment of the pneumococcal pneumonias. N Engl J Med. 1940;222:739-747.
13. Flippin HF. Sulfapyridine in the treatment of pneumococci pneumonia based upon treatment of 350 cases. 1939. Chest. 2009;136(suppl):e30.
14. Flippin HF, Lockwood JS, Pepper DS, et al. The treatment of pneumococcic pneumonia with sulfapyridine: a progress report on observations in 100 cases. J Am Med Assoc. 1939;112:529-534.
15. Meakins JC, Hanson FR. The treatment of pneumococcic pneumonia with sulfapyridine. Can Med Assoc J. 1939;40:333-336.
16. Wilson AT, Spreen AH, Cooper ML, et al. Sulfapyridine in the treatment of pneumonia in infancy and childhood. J Am Med Assoc. 1939;112:1435-1439.
17. File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(suppl):iii19Yiii32.
18. Low DE, File TM Jr, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(suppl):iii33Yiii44.
19. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl):S27YS72.
20. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226.
21. Arnold FW, LaJoie AS, Brock GN, et al; Community-Acquired Pneumonia Organization (CAPO) Investigators. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International Cohort Study results. Arch Intern Med. 2009;169:1515-1524.
22. Arnold FW, Brock GN, Peyrani P, et al; CAPO authors. Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med. 2010;104:1736-1743.
23. Fishbane S, Niederman MS, Daly C, et al. The impact of standardized order sets and intensive clinical case management on outcomes in community-acquired pneumonia. Arch Intern Med. 2007;167:1664-1669.
24. Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155:1273-1276.
25. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999;159:2449-2454.
26. Aliberti S, Peyrani P, Filardo G, et al. Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. Chest. 2011;140:482-488.
27. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med. 2002;162:682-688.
28. Huang JQ, Hooper PM, Marrie TJ. Factors associated with length of stay in hospital for suspected community-acquired pneumonia. Can Respir J. 2006;13:317-324.